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Abstract To evaluate the prevalence of past infection
with hepatitis B virus (HBV) in patients with rheumatoid
arthritis (RA) and the incidence of its reactivation under
treatment with biological and/or nonbiological disease-
modifying antirheumatic drugs (DMARDs), 239 patients
receiving DMARD therapy were consecutively enrolled
and tested for HBV-DNA, using a real-time polymerase
chain reaction assay, HBV serology including hepatitis B
surface antigen (HBsAg) and hepatitis B core antibody
(anti-HBc), and serum levels of aminotransferase. Data
prior to DMARD therapy and during follow-up were
examined by reviewing medical records. Two patients
(0.8%) were positive for HBsAg at the start of therapy.
Sixty patients (25.1%) showed HBsAg-negative and anti-
HBc-positive serology indicative of past HBV infection.
Among these 60 patients, 2 patients (3.3%) experienced
reactivation of viral replication (\2.1 log copies/ml) dur-
ing DMARD therapy. One had been receiving tacrolimus,
prednisolone, and methotrexate (MTX); the other had been
treated with adalimumab, prednisolone, and MTX. Their
serum aminotransferase levels remained normal, and
HBsAg was negative. Ten weeks after reactivation of viral
replication had been noted, the HBV-DNA titer in the
former patient had increased to 2.9 log copies/ml, and
HBsAg and hepatitis B e antigen had become weakly
positive. In contrast, the latter patient had become negative
for viral DNA without any antiviral prophylaxis. In con-
clusion, the use of biological and nonbiological DMARDs
is relatively safe in most RA patients with past HBV
infection, even when no anti-HBV prophylaxis is admin-
istered. Considering the high prevalence of past infection in
RA patients and the high cost of prophylaxis against HBV
reactivation, universal prophylaxis is impractical. Regular
monitoring of serum viral DNA seems to be the most
rational approach to preventing the development of clini-
cally apparent hepatitis.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inﬂam-
matory disorder characterized by uncontrolled synovial
proliferation in multiple joints. Most patients, if left
untreated or inadequately treated, suffer from relentless
progressive polyarthritis, causing bone erosion, joint
destruction and deformity, and disability, with resultant
deterioration in quality of life. Over the past decade,
however, the treatment of RA has dramatically changed. It
is now well established that when therapy with disease-
modifying antirheumatic drugs (DMARDs) is instituted
within a few months of disease onset, clinical outcomes are
markedly improved [1, 2]. Synthetic DMARDs have been
in use for several decades; among these, methotrexate
(MTX) is now the most commonly utilized as the ﬁrst-line
DMARD of choice. Further, the emergence of innovative
biological agents that target speciﬁc molecules and path-
ways in the immune system has strikingly changed the
course of RA and outcomes for patients and society. The
use of these biological and nonbiological DMARDs is,
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increased risk of serious infectious complications, espe-
cially those caused by Mycobacterium tuberculosis, atyp-
ical mycobacteria, Pneumocystis jirovecii, and other
opportunistic bacterial and fungal infections [3–5]. In
addition, a number of chronic viral infections can be
reactivated during immunosuppressive therapy for rheu-
matic disease [6].
Reactivation of hepatitis B virus (HBV) replication is a
well-recognized complication in patients receiving short-
term chemotherapy for malignancies or long-term immu-
nosuppressive therapy after transplantation [7]. HBV
reactivation has also been noted in patients treated with
synthetic DMARDs, biological agents, and/or high-dose
prednisolone for rheumatic disease [8]. Scientiﬁc organi-
zations and health authorities around the world have pro-
posed various recommendations for managing patients with
chronic HBV infection [9], especially those undergoing
immunosuppressive therapy [10, 11]. Rheumatology soci-
eties have also published guidelines regarding the use of
biological and nonbiological DMARDs in patients with
chronic HBV infection [1]; however, more speciﬁc con-
sensus guidelines/recommendations on screening practices
for HBV infection may be required prior to initiating
immunosuppressive therapy for rheumatic disease [12, 13].
Calabrese et al. [8] have recommended screening for HBV
markers, including hepatitis B surface antigen (HBsAg),
antibody against HBsAg (anti-HBs), and antibody against
hepatitis B core antigen (anti-HBc), for all patients with
rheumatic diseases requiring immunosuppressive agents
that have the potential to induce HBV reactivation.
Patients found to be HBsAg-positive are considered to
have a current HBV infection; for these patients, who can
include active and inactive carriers, antiviral prophylaxis is
necessary before starting immunosuppressive therapy [10,
11]. Patients who are positive for anti-HBc and negative for
HBsAg are considered to have had a past HBV infection;
these patients may be occult carriers; that is, HBsAg-neg-
ative individuals with a long-lasting persistence of viral
genomes in the liver tissue and/or serum at very low levels
[14, 15]. Currently, all anti-HBc-positive/HBsAg-negative
individuals are regarded as potential occult carriers. In
addition, occult infection is sometimes found in patients
without any serological HBV markers [16]. Data regarding
the prevalence of occult infection and the incidence of its
reactivation in RA patients under treatment with biological
and/or nonbiological DMARDs are still limited and
somewhat controversial [17–22]. The optimal protocol for
treating such patients is therefore unclear.
To address this issue, I consecutively enrolled 239 RA
patients who had been treated with biological and/or non-
biological DMARDs and determined their serum levels of
HBV-DNA, status of serological HBV markers, and levels
of serum aminotransferase. Data prior to and during
DMARD therapy were examined by reviewing medical
records.
Patients, materials, and methods
Patients
In October and November of 2010, 239 Japanese patients
under treatment with biological and/or nonbiological
DMARDs for RA were consecutively enrolled at our out-
patient clinic. All participants fulﬁlled the 1987 American
CollegeofRheumatology(ACR)criteriaforthediagnosisof
RA. Serum levels of HBV-DNA, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST), as well as the
status of HBsAg and anti-HBc, were determined at enroll-
ment.DataonserologicalHBVmarkersandserumALTand
AST levels prior to DMARD therapy and during follow-up
(at each visit, i.e., once every 2–3 months) were examined
by reviewing the patients’ medical records. The ethics
committee of our hospital approved the protocol for this
study, and informed consent was obtained from all patients.
Quantiﬁcation of HBV-DNA and detection
of serological HBV markers
HBV-DNA quantiﬁcation was performed at SRL (Tac-
hikawa, Tokyo, Japan) by real-time polymerase chain
reaction (PCR) assay (COBAS AmpliPrep/COBAS Taq-
Man HBV Test version 2; Roche Diagnostics Japan,
Tokyo, Japan). The detection threshold was 19 IU/ml
(2.0 log copies/ml) when serum was used as a specimen.
The quantiﬁable range of this assay was 2.1–9.0 log cop-
ies/ml. Serological HBV markers (HBsAg and anti-HBc)
were all detected using chemiluminescence immunoassays
(ARCHITECT System; Abbott Japan, Tokyo, Japan).
Statistical analysis
In analyses of categorical variables, levels of signiﬁcance
were determined by means of the v
2test, using 2 9 2 con-
tingency tables. Continuous variables were assessed using
the Mann–Whitney U-test. For all tests, probability values
(p values) of\0.05 were considered to indicate statistical
signiﬁcance. All calculations were performed using Excel
Statistical Analysis 2008 (SSRI, Tokyo, Japan).
Results
Among the 239 participants, 2 patients (0.8%) were posi-
tive for HBsAg when DMARD therapy was ﬁrst
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123introduced; these patients had been diagnosed as inactive
HBV carriers and had been started on anti-HBV prophy-
laxis with entecavir (0.5 mg/day), based on the recom-
mendation of a hepatologist prior to the commencement of
anti-RA therapy. Entecavir was continued during the
DMARD therapy (one patient receiving 8 mg/week of
MTX and additional tacrolimus; the other receiving 8 mg/
week of MTX and additional etanercept), and no reacti-
vation of viral replication was observed, as evidenced by
the absence of any increases in ALT/AST levels or HBV-
DNA titer. The other patients (n = 237) tested negative for
HBsAg at the start of DMARD therapy, and were classiﬁed
into two groups according to their baseline anti-HBc status
(Table 1); namely, an HBsAg-negative/anti-HBc-positive
group (individuals with past HBV infection, n = 60, 25.1%
of all participants) and the HBsAg-negative/anti-HBc-
negative group (n = 177, 74.1%). No change in anti-HBc
status was seen in either patient group during follow-up.
These patients did not receive any antiviral prophylaxis
during anti-RA therapy. At the time of enrollment, the
median age of the anti-HBc-positive group was signiﬁ-
cantly greater than that of the anti-HBc-negative group (73
vs. 62 years, p = 0.0002). There were no signiﬁcant dif-
ferences in serum levels of AST or ALT between the
groups. The serum AST level was more than twice the
upper limit of the normal range in 1 patient (76 IU/l, 1.7%)
in the anti-HBc-positive group and 3 patients (73, 75, and
87 IU/l, 1.7%) in the HBc-negative group; no patients
showed a twofold or greater increase in serum ALT levels
as compared with the upper limit of normal. Only 1 patient
in the anti-HBc-negative group tested positive for anti-
hepatitis C virus antibody.
With the real-time PCR assay, HBV-DNA was not
detected in the sera of any anti-HBc-negative patients. In
the anti-HBc-positive group, however, 2 patients (3.3%)
tested positive for serum HBV DNA, but the titers in these
patients were very low (\2.1 log copies/ml). Both were
negative for HBsAg, and their serum levels of AST and
ALT were within the normal ranges (cases 1 and 2;
Table 2). One year previously, case 1 had been treated with
MTX (8 mg/week), but her RA was not adequately con-
trolled. At that time, the patient had tested negative for
serum HBV DNA. Nine months before enrollment in the
present study, she had been treated with high-dose pred-
nisolone (40 mg/day for 10 days, orally) for minimal-
change nephrotic syndrome. The prednisolone was then
tapered off to 5 mg/day. Subsequently, this patient was
restarted on anti-RA therapy with MTX (8 mg/week),
Table 1 Characteristics of RA patients at the time of enrollment, grouped according to the baseline anti-HBc status (n = 237)
Anti-HBc negative-group
(n = 177)
Anti-HBc-positive
group (n = 60)
p*
Male/female 43/134 22/38 0.06
Age, years, median (25th, 75th percentiles) 62 (56, 72) 73 (61, 78) 0.0002
RA duration, months, median (25th, 75th percentiles) 58 (24, 113) 54 (33, 89) 0.36
AST, IU/l, median (25th, 75th percentiles) 23 (19, 28) 24 (20, 28) 0.77
ALT, IU/l, median (25th, 75th percentiles) 20 (15, 27) 18.5 (14, 27) 0.78
Positive HBsAg, number of patients (%) 0 0 –
Current and previous DMARDs
Number of patients (%)/duration, months,
median (25th, 75th percentiles)
Methotrexate (6–10 mg/week) 165 (93.2)/43 (17, 57) 54 (90)/34 (11.5, 52) –
Tacrolimus (1–2 mg/day) 41 (23.2)/19 (9, 37) 30 (50)/19.5 (6, 29) –
Leﬂunomide (20 mg/day) 2 (1.1)/(20, 54)
a 0–
Anti-TNFa agents 95 (53.7)/24 (5.5, 41) 31 (51.7)/12 (6, 29.5)
Inﬂiximab 63 (35.6)/19 (3.5, 30) 19 (31.7)/5 (3, 17) –
Etanercept 55 (31.1)/17 (4, 32.5) 18 (30)/10 (6, 25) –
Adalimumab 4 (2.3)/3.5 (2.8, 6.5) 2 (3.3)/(15, 15)
a –
Tocilizumab 15 (8.5)/10 (2.5, 11) 5 (8.3)/6 (5, 7) –
Prednisolone (5 mg/day) 99 (55.9) 38 (63.3) –
Patients who were HBsAg-positive at the introduction of anti-RA therapy (n = 2) were not included
RA rheumatoid arthritis, DMARDs disease-modifying antirheumatic drugs, Anti-HBc antibody against hepatitis B core antigen, HBsAg hepatitis
B surface antigen, AST aspartate aminotransferase, ALT alanine aminotransferase, anti-TNFa anti-tumor necrosis factor a
* p values are based on comparison between anti-HBc-negative and anti-HBc-positive groups
a Numbers in parentheses are actual duration of therapy for each patient (months)
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123prednisolone (5 mg/day), and tacrolimus (1 mg/day).
Before enrollment, the patient had never shown positive
results for serum HBsAg or abnormal liver function.
Whether her high-dose use of prednisolone for a short
period may have been associated with the viral reactivation
observed was not clear. Case 2 had previously been treated
unsuccessfully with anti-tumor necrosis factor a (anti-
TNFa) therapy with inﬂiximab (48 months) and etanercept
(4 months); at the time of enrollment, she had been
receiving therapy consisting of adalimumab, MTX (6 mg/
week), and prednisolone (5 mg/day) for 15 months. It is
uncertain when HBV DNA appeared in this patient’s
serum, as no increases in serum levels of AST or ALT were
observed in regular checkups during anti-RA therapy. In
addition, no positive serology for HBsAg was observed
throughout this period.
Two months after the viral reactivation had been noted in
case 1, the HBV-DNA titer had increased (2.8 log copies/
ml), though HBsAg was still negative and serum levels of
aminotransferase remained within the normal range. Two
weeks after that time, HBsAg and HBeAg became weakly
positive (0.14 IU/ml and 2.8 S/CO, respectively) and the
HBV-DNA titer was 2.9 log copies/ml. No abnormal liver
function was observed. The patient was started on anti-HBV
prophylaxis with entecavir. In contrast, in case 2, HBV
DNA spontaneously disappeared from the patient’s sera.
Discussion
The prevalence of past HBV infection was 25.1% among
the RA patients enrolled in the present study. During bio-
logical and/or nonbiological DMARD therapy without anti-
HBV prophylaxis, viral DNA reappeared in the serum
(\2.1 log copies/ml) in 3.3% of the patients with past HBV
infection (2 patients), though serum aminotransferase lev-
els were within the normal range and HBsAg was negative.
Two months after the reappearance of viral DNA in the
serum, the HBV-DNA titer in one patient had increased to
2.8 log copies/ml, whereas the other patient had become
negative for viral DNA without any prophylaxis. These
ﬁndings suggest that the use of biological and nonbiolog-
ical DMARDs is relatively safe in most RA patients pre-
viously exposed to HBV, even when no anti-HBV
prophylaxis is administered. Nevertheless, regular moni-
toring of viremia is desirable to prevent the development of
clinically apparent hepatitis.
Most recent reports from European countries have
shown that anti-TNFa therapy appears to be quite safe for
patients with rheumatic diseases and past HBV infection,
because no reactivation of HBV replication with viral load
increases was found even in the absence of antiviral pro-
phylaxis [18–20]. In these studies, the detection threshold
of HBV-DNA ranged from 1.7 to 2.5 log copies/ml, the
number of patients with past HBV infection ranged from
19 to 67, and the mean follow-up period ranged from 12 to
43 months. A prospective study for Japanese patients with
RA and resolved HBV infection has shown that without
any anti-HBV prophylaxis, viral reactivation occurred in
only one out of 45 patients (2.2%) during immunosup-
pressive therapy with conventional DMARDs and/or anti-
TNFa agents for a mean period of 23 months (range 12–32
months) [22]. In the same study, signiﬁcant decreases in
anti-HBs levels were observed in patients who had
received anti-TNFa agents, especially those with low anti-
HBs titers at baseline; however, no reactivation of HBV
replication was found in this patient population. In the
present study, 31 patients with past HBV infection had
Table 2 Characteristics of RA
patients with HBV-DNA
detected in serum during
DMARD therapy
Data were obtained at the time
of enrollment
RA rheumatoid arthritis,
HBV hepatitis B virus,
DMARD disease-modifying
antirheumatic drug,
AST aspartate aminotransferase,
ALT alanine aminotransferase,
Anti-HBc antibody against
hepatitis B core antigen,
HBsAg hepatitis B surface
antigen, PSL prednisolone,
MTX methotrexate
Case 1 Case 2
Male/female F F
Age (years) 67 80
RA duration (months) 540 276
AST, IU/l (normal range 13–33 IU/l) 8 18
ALT, IU/l (normal range 6–42 IU/l) 13 25
Anti-HBc Positive Positive
HBsAg Negative Negative
Current and previous DMARDs (months)
Methotrexate (MTX) 42 86
Tacrolimus 5 -
Inﬂiximab - 48
Etanercept - 4
Adalimumab - 15
Prednisolone (PSL) ??
Current therapy MTX ? tacrolimus ? PSL MTX ? adalimumab ? PSL
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12 months without antiviral prophylaxis. Among these
patients, only one patient (3.2%) showed a slight increase
in HBV-DNA titer; 2 months after this increase, however,
viral DNA had disappeared without any prophylaxis.
Antiviral prophylaxis may not be routinely necessary for
patients with past HBV infection who are scheduled to
receive anti-TNFa therapy, if virological and clinical fol-
low-up is conducted regularly for the early detection of
HBV reactivation [8, 23].
In contrast to the above ﬁndings, several cases of HBV
reactivation with viremia and emergence of HBsAg have
been reported in patients with past HBV infection during
immunosuppressive therapy for Crohn’s disease, ankylos-
ing spondylitis, and RA [24–26]. Most recently, Urata et al.
[21] have reported a high prevalence of HBV reactivation
with marked increases in viral load in Japanese patients
with RA and resolved HBV infection. In their study, 7 out
of 135 patients (5.2%) in the resolved infection group
became positive for HBV DNA (equal to or higher than
3.64 log copies/ml) at some point during a 12-month per-
iod of therapy. Notably, 52 patients with resolved HBV
infection had been treated with biological agents; among
these, 6 (11.5%) had HBV reactivation with an increased
titer of viral DNA. Two patients showed particularly high
levels of viremia (5 and 7.4 log copies/ml, respectively).
The data on these 52 patients treated with biological agents
suggest that RA patients with resolved HBV infection may
be at a greater risk of reactivation of HBV when biological
rather than nonbiological DMARDs are used for RA
therapy. In the present study, however, no such tendency
was evident when patients receiving anti-TNFa therapy
and anti-TNFa-naı ¨ve patients were compared.
Kim et al. [17] have reported that, during anti-TNFa
therapy for rheumatic diseases (median duration
25–27 months), clinically signiﬁcant and persistent rises in
serum levels of aminotransferase were observed at higher
rates in a patient group with potential occult HBV infection
(n = 88) than in the anti-HBc-negative group (n = 170),
although viral load in these patients was not determined.
Fourteen patients (15.9%) in the former group showed
abnormal liver function, deﬁned as a serum aminotrans-
ferase level at least twice the upper limit of normal. Using
multiple logistic regression analysis, Kim and colleagues
indicated that the presence of past infection was a signiﬁ-
cant risk factor associated with abnormal liver function,
suggesting that serum aminotransferase may be used as a
surrogate marker of possible reactivation of occult infec-
tion. In the present study, however, only one patient with
past HBV infection presented with similar abnormal liver
function; there was no difference in the rate of patients
presenting with abnormal levels of serum aminotransferase
between the anti-HBc-positive and -negative groups. In
addition, the patients showing detectable levels of serum
HBV-DNA had maintained serum ALT and AST levels
within the normal ranges.
Prophylactic antiviral therapy has been recommended
for HBsAg-positive patients receiving anti-TNFa agents,
because such individuals are considered to be at high risk
for viral reactivation [27–30]. At our institute, the pro-
phylactic use of entecavir is indicated for HBsAg-positive
patients who are scheduled for DMARD therapy. If RA is
inadequately controlled despite treatment for at least
3 months with standard doses of conventional DMARDs,
we consider biological DMARD therapy under close
observation of HBV-DNA titers and ALT/AST levels.
Entecavir has demonstrably potent anti-HBV activity, and
long-term follow-up studies have shown that it confers
sustained suppression of viral replication, yet has a low
incidence of drug resistance and good tolerability, making
it an ideal ﬁrst-line agent for prolonged treatment of
HBsAg carriers [31–33]. In the present study, 2 inactive
HBsAg carriers had been started on anti-HBV prophylaxis
with entecavir prior to the commencement of DMARD
therapy and no reactivation of viral replication was
observed. Likewise, Tamori et al. [22] have reported that
among 5 patients positive for HBsAg, 3 pretreated with
entecavir continued to receive MTX or etanercept without
hepatic ﬂares, whereas HBV reactivation occurred in the
remaining 2 patients who had not received anti-HBV pro-
phylaxis. The question is whether concomitant treatment
with entecavir may be necessary for patients with past
HBV infection and RA requiring an extended course of
DMARD therapy including biological agents. HBV infec-
tion is one of the most common viral infections in humans,
and Japan is one of its endemic areas: another group has
reported that the prevalence of resolved HBV infection is
31.5% among Japanese RA patients [21], and 25% of the
RA patients enrolled in the present study exhibited a
serological pattern indicating past HBV infection. In
addition, it is known that more than 20% of occult HBV
carriers are negative for all HBV serological markers [16].
In the present study, the incidence of reactivation of HBV
replication among this patient population was low even
without antiviral prophylaxis. Although it cannot be denied
that HBV reactivation occasionally leads to life-threatening
liver failure [34], anti-HBV prophylaxis with entecavir is
very expensive to maintain throughout long courses of
therapy for RA; given the low incidence of HBV reacti-
vation, anti-HBV prophylaxis may not be cost-effective. It
therefore seems impractical to give prophylactic agents to
all RA patients with past HBV infection who are to receive
biological and nonbiological DMARDs.
The major ﬁndings of the present study are that HBsAg-
negative/anti-HBc-positive serology was observed in one-
fourth of RA patients and that the use of biological and
Mod Rheumatol (2011) 21:621–627 625
123nonbiological DMARDs is relatively safe in most RA
patients with past HBV infection. Considering the inher-
ently long-term nature of anti-RA therapy and the high
costs of anti-HBV prophylaxis, universal prophylaxis for
patients with RA and past HBV infection seems impracti-
cal. Careful monitoring of serum viral load seems to be the
most rational approach to managing RA patients with past
HBV infection who require anti-RA therapy.
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